Pokomoke, MD (PRWEB) October 24, 2013
Dr. Ritchie Shoemaker, education pioneer and leader in patient care and research in the field of biotoxin related illnesses, announced last week that another physician has completed the Shoemaker Protocol Certification Program. Dr. Robin Thomson, of Bozeman, Montana, becomes just the fifth ever to have completed the one-on-one training program.
“Dr. Thomson is now able to bring her expertise to a part of the country that has not been able to treat CIRS patients with the most effective protocol,” said Dr. Shoemaker. “This brings us another step closer to a nationwide network of Shoemaker Protocol Certified physicians. We are thrilled to introduce Dr. Robin Thomson as the newest graduate of the program.“ Dr. Thomson is a graduate of the National College of Naturopathic Medicine in Portland, Oregon, and studied Lyme and related infections with Dr. Bernard Raxlen in New York City on a grant from the Turn the Corner Foundation.
Chronic Inflammatory Response Syndrome (CIRS) is an auto-immune reaction to biotoxins such as those found in the interior of water damaged buildings, resulting in dramatic, life-changing health problems. According to Dr. Shoemaker’s research, approximately 25% of the population is genetically pre-disposed to contracting CIRS. Dr. Robin Thomson is the owner of Trillium Integrative Medicine in Bozeman, and a naturopathic physician specializing in treating tick-borne disease and other issues. She undertook the certification process earlier in 2013 after realizing a ‘missing piece’ in her patient’s disease process.
About Ritchie Shoemaker – Ritchie Shoemaker, MD, has treated over 6,000 patients, and written numerous papers and eight books, including the widely read Surviving Mold. He is recognized internationally as the leader in the field of biotoxin related illness. Having retired from active patient care in January, 2013, Dr. Shoemaker remains dedicated to developing a nationwide network of physicians certified in the Shoemaker Protocol, giving lectures on the subject, and continuing his research in the biotoxin related illness field.